Baidu
map

Ann Neurol:血管内治疗成功后的血压目标值和临床结局

2020-03-21 MedSci原创 MedSci原创

由此可见,应用EVT成功进行血运重建后,SBP<140和<160mmHg的目标值似乎比SBP<180mmHg具有更好的临床结局。

血管内治疗(EVT)成功进行血运重建后收缩压(SBP)升高是不良预后的已知预测因子。然而,EVT后的最佳SBP目标值仍然未知。近日,神经病学领域权威取杂志Annals of Neurology上发表了一篇研究文章,研究人使旨在比较血管重建术(SR)后不同SBP目标患者的功能和安全性结局。

这项国际多中心研究纳入了8个综合性卒中中心,研究人员将采用EVT治疗并达到SR的前循环LVO患者纳入研究。SR定义为mTICI(改良的脑缺血溶栓)为2b‐3。根据EVT术后24小时内的SBP指标将患者分为三组。研究人员采用治疗加权逆概率(IPTW)倾向分析评估不同SBP目标对临床结局的影响。

该研究共纳入1019例患者。在IPTW分析中,与SBP目标值<180mmHg相比,SBP目标值<140mmHg组具有更高的良好功能预后可能性和更低的半鼻梁切除术的可能性。同样,与SBP目标值<180mmHg相比,SBP目标值<160mmHg与更低的死亡率相关。在仅纳入EVT前SBP≥140mmHg患者的亚组分析中,与SBP目标值<180mmHg相比,SBP<140mmHg与更高的良好功能预后可能性、更低的sICH发生率、更低的半鼻梁切除术需求有关。

由此可见,应用EVT成功进行血运重建后,SBP<140和<160mmHg的目标值似乎比SBP<180mmHg具有更好的临床结局。

原始出处:

Mohammad Anadani,et al.Blood Pressure Goals and Clinical Outcomes after Successful Endovascular Therapy: A Multicenter Study.Annals of Neurology. 2020.https://doi.org/10.1002/ana.25716

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000997, encodeId=9cb3200099ea4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 13 15:28:01 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078149, encodeId=33b420e8149de, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jun 01 03:28:01 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843214, encodeId=faa718432147c, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Nov 26 15:28:01 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
    2020-04-13 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000997, encodeId=9cb3200099ea4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 13 15:28:01 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078149, encodeId=33b420e8149de, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jun 01 03:28:01 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843214, encodeId=faa718432147c, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Nov 26 15:28:01 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000997, encodeId=9cb3200099ea4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Apr 13 15:28:01 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078149, encodeId=33b420e8149de, content=<a href='/topic/show?id=86ec889615b' target=_blank style='color:#2F92EE;'>#血压目标值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88961, encryptionId=86ec889615b, topicName=血压目标值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Jun 01 03:28:01 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843214, encodeId=faa718432147c, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Nov 26 15:28:01 CST 2020, time=2020-11-26, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map